Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Anusha Pampana"'
Autor:
Poornachandra G, Annapoorna Prakash, Prashant Ramachandran Nair, Anusha Pampana, Deepak Anil Lala, Vishwas Joseph, Kunal Ghosh Roy, Shruthi Kulkarni, Ashish Agarwal, Shweta Kapoor, Michael Castro, Rajan Parashar, Swaminathan Rajagopalan, Nikita Ray Choudhary, Liptimayee Behura, Aftab Alam, Sayani Basu
Publikováno v:
Journal of Neuro-Oncology
Background A randomized trial in glioblastoma patients with methylated-MGMT (m-MGMT) found an improvement in median survival of 16.7 months for combination therapy with temozolomide (TMZ) and lomustine, however the approach remains controversial and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f345e09393d836963bc1ae0fa97ba9fd
https://doi.org/10.1007/s11060-021-03780-0
https://doi.org/10.1007/s11060-021-03780-0
Autor:
Michael Castro, Fabio Iwamoto, Manmeet Ahluwalia, Shahabuddin Usmani, Ansu Kumar, Shweta Kapoor, Rakhi Purushothaman Suseela, Shruthi Kulkarni, Jharana Mohanty, Vijayashree Shyamasundar, Adity Ghosh, Nagendra Prasad, Mamatha Patil, Sayantani Roy Choudhury, Jyoti Chauhan, Mohammed Sauban, Vishwas Joseph, Pallavi Kumari, Upasana Mitra, Anusha Pampana, Humera Azam, Poornachandra G, Annapoorna Prakash, Sayani Basu
Publikováno v:
Neuro-Oncology. 24:vii116-vii117
BACKGROUND TMZ-induced G:T mismatches trigger MMR to perform futile repair of O6-methylguanine leading to apoptosis. Without MMR, the G:T mutation is genomically incorporated to produce DNA mutation signature #11. Hypermutation ensues and may comprom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d29f1c35e5841cab7e506296b2cf128f
https://doi.org/10.1093/neuonc/noac209.441
https://doi.org/10.1093/neuonc/noac209.441
Autor:
Aftab Alam, Divya Singh, Liptimayee Behura, Anusha Pampana, Anish Raju R Amara, Negar Khanlou, Kunal Ghosh Roy, Michael Castro, Annapoorna Prakash, Ansu Kumar, Shweta Kapoor, Deepak Anil Lala, Aria Fallah
Publikováno v:
Annals of Translational Medicine. 10:1289-1289
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1730ac896995ddb5cc0bed4c0f17c62
https://doi.org/10.21037/atm-2022-62
https://doi.org/10.21037/atm-2022-62
Autor:
Leylah Drusbosky, Shireen Vali, Shahabuddin Usmani, Shivgonda C. Birajdar, Ansu Kumar, Christopher R. Cogle, P. R. K. Bhargav, Anuj Tyagi, Aftab Alam, Taher Abbasi, Amy Meacham, Deepak Anil Lala, Anusha Pampana, Kunal Ghosh Roy, Sumanth Vasista, Girish Chinnaswamy, Madeleine Turcotte, Swaminathan Rajagopalan, Manju Sengar, Bijal D. Shah, Kabya Basu
Publikováno v:
Leukemia Research. 78:3-11
Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is an aggressive hematological malignancy for which optimal therapeutic approaches are poorly characterized. Using computational biology modeling (CBM) in conjunction with genomic data fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b94335dec673fb2e00db38752a823892
https://doi.org/10.1016/j.leukres.2019.01.003
https://doi.org/10.1016/j.leukres.2019.01.003
Autor:
Elizabeth Catherine Smyth, Drew Watson, Barbara Nutzinger, Michael P Castro, Shweta Kapoor, Samiksha Avinash Prasad, Swaminathan Rajagopalan, Calvin Cheah, Prashant Ramachandran Nair, Aftab Alam, Ginny Devonshire, Nicola Grehan, Rakhi Purushothaman Suseela, Anuj Tyagi, Ashish Kumar Agrawal, Humera Azam, Mohammed Sauban, Anusha Pampana, Michele Dundas Macpherson, Rebecca C. Fitzgerald
Publikováno v:
Journal of Clinical Oncology. 40:4064-4064
4064 Background: Computational biological modeling reveals many dysregulated signaling pathways responsible for hallmark behaviors of cancer and variable drug response in the population. A mechanistic model created for each patient using comprehensiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60368034bc1c9907be0492521320270f
https://doi.org/10.1200/jco.2022.40.16_suppl.4064
https://doi.org/10.1200/jco.2022.40.16_suppl.4064
Autor:
Shruthi Kulkarni, Yugandhara Narvekar, Scott C. Howard, Himanshu Grover, Rahul K Raman, Anusha Pampana, Anuj Tyagi, Prashant Ramachandran Nair, Michele Dundas Macpherson, Deepak Anil Lala, S. Mohapatra, Ansu Kumar, Kritika Sahni, Shweta Kapoor, Michael Castro, Nirjhar Mundkur, Vijayashree P Shyamasundar, Ashokraja Balla, Guido Marcucci, Mamatha Patil, Rakhi Purushothaman Suseela, James Christie, Divya Singh, Naga Ganesh Palaniyeppa, Veena Balakrishnan, Sanjana Patel
Publikováno v:
Blood. 138:3690-3690
Background: DNA methyltransferase inhibition (DNMTi) with the hypomethylating agents (HMA) azacitidine (AZA) or decitabine, remains the mainstay of therapy for the majority of high-risk Myelodysplastic Syndromes (MDS) patients. Nevertheless, only 40-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd4abf95e42ad7109ca7566872efd810
https://doi.org/10.1182/blood-2021-153539
https://doi.org/10.1182/blood-2021-153539
Autor:
Drew Watson, Yashaswini S Ullal, Scott C. Howard, Ashish Kumar Agrawal, Michael Castro, Diwyanshu Sahu, Mohammed Sauban, Kabya Basu, Shweta Kapoor, Anusha Pampana, Rakhi Purushothaman Suseela, Anuj Tyagi, Poornachandra G, Yugandhara Narvekar, Adity Ghosh, Prashant Ramachandran Nair, Deepak Anil Lala, Karthik Sundara Raju, Sanjana Patel, Samiksha Avinash Prasad, James Christie, Kunal Ghosh Roy, Nirjhar Mundkur, Swaminathan Rajagopalan, Aftab Alam, Guido Marcucci, Michele Dundas Macpherson
Publikováno v:
Blood. 138:689-689
Background: Although some genomic biomarkers have been integrated into therapeutic decision-making for the management of AML, the complete remission and cure rates have significant margin for improvement. Except for a few targeted therapies, genomic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e24335c185e27199996160bcd63a7a97
https://doi.org/10.1182/blood-2021-154023
https://doi.org/10.1182/blood-2021-154023
Autor:
Rakhi Purushothaman Suseela, Ashish Kumar Agrawal, Scott C. Howard, Nirjhar Mundkur, Shweta Kapoor, Ansu Kumar, Prashant Ramachandran Nair, Michael Castro, Vivek R. Shinde Patil, Diwyanshu Sahu, Kabya Basu, Pallavi Kumari, Nagendra K. Prasad, Sanjana Patel, Mohammed Sauban, Archana Palillam Veedu, James Christie, Yashaswini S Ullal, Himanshu Grover, Chandan Kumar, Nithya T Raveendaran, Michele Dundas Macpherson, Anusha Pampana, Samiksha Avinash Prasad, Humera Azam, Anish Raju R Amara
Publikováno v:
Blood. 138:2615-2615
Background: DNA methyltransferase inhibition (DNMTi) with hypomethylating agents (HMA), azacitidine (AZA) or decitabine (DAC), remains the mainstay of therapy for most high-risk Myelodysplastic syndrome (MDS) patients. However, only 40-50% of MDS pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1970903484a6dda996fc07532b0404bf
https://doi.org/10.1182/blood-2021-153220
https://doi.org/10.1182/blood-2021-153220
Autor:
Scott C. Howard, Anuj Tyagi, Ansu Kumar, Yashaswini S Ullal, Vishwas Joseph, Prashant Ramachandran Nair, Pallavi Kumari, Veena Balakrishnan, Anusha Pampana, Nirjhar Mundkur, Michele Dundas Macpherson, Shweta Kapoor, Deepak Anil Lala, Karthik Sundara Raju
Publikováno v:
Blood. 136:18-19
Background:Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL), an orphan disease, is a sub-type of T-Cell Acute Lymphoblastic Leukemia (T-ALL) with very poor prognosis and limited therapy options. ETP-ALL is a heterogeneous disease with ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00d6dd9ad4bbebec5a7dced657c78a13
https://doi.org/10.1182/blood-2020-139997
https://doi.org/10.1182/blood-2020-139997
Autor:
Manmeet Ahluwalia, Sayani Basu, Prashant Ramachandran Nair, Shweta Kapoor, Yugandhara Narvekar, Michael Castro, Diwyanshu Sahu, Patrick Y. Wen, Kabya Basu, Ashish Kumar Agrawal, Divya Singh, Deepak Anil Lala, Drew Watson, Kunal Ghosh Roy, Nirjhar Mundkur, Swaminathan Rajagopalan, Anusha Pampana, Jim Christie, Aftab Alam
Publikováno v:
Journal of Clinical Oncology. 39:2017-2017
2017 Background: The Cellworks Singula Therapeutic Response Index (TRI) has been developed to assist clinicians and GBM patients in choosing between competing therapeutic options. In contrast to approaches that consider single aberrations, which ofte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b07fa82a9f7f575392e009cf06365b8e
https://doi.org/10.1200/jco.2021.39.15_suppl.2017
https://doi.org/10.1200/jco.2021.39.15_suppl.2017